- Bestsellers
- Alcoholism
- COVID-19
- Allergy
- Anti Fungal
- Alzheimers
- Anti Viral
- Anti-Depressants
- Anti-Inflammatory
- Antibacterial
- Antiparasitic
- Antibiotics
- Arthritis
- Asthma
- Birth Control
- Blood Pressure
- Cancer
- Cardiovascular
- Cholesterol
- Diabetes
- Diuretics
- Erectile Dysfunction
- Eye Drop
- Gastro Health
- General Health
- Hair Loss
- Hepatitis C Virus (HCV)
- HIV
- Hormones
- Men's ED Packs
- Men's Health
- Mental Illness
- Motion Sickness
- Muscle Relaxant
- Pain Relief
- Parkinson’s Disease
- Veterinary Medicines
- Quit Smoking
- Vitamins
- Skin Care
- Sleeping Aids
- Weight Loss
- Women's Health
Generic Tasigna ( Nilotinib )
Tasigna (nilotinib) is a tyrosine kinase inhibitor indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (CML) in chronic phase, and for adult patients with chronic or accelerated phase CML who are resistant or intolerant to prior therapy including imatinib. Nilotinib works by selectively inhibiting the BCR‑ABL tyrosine kinase, the abnormal enzyme produced by the Philadelphia chromosome, as well as other kinases such as PDGFR and c‑KIT. By blocking these signalling pathways, Tasigna prevents the uncontrolled proliferation of leukemic cells. It is a second‑generation BCR‑ABL inhibitor with higher potency than imatinib.
Usual adult dose: For newly diagnosed chronic phase CML, the recommended dose is 300 mg twice daily, taken orally approximately 12 hours apart. For patients with chronic or accelerated phase CML resistant or intolerant to prior therapy, the dose is 400 mg twice daily. The 150 mg and 200 mg capsule strengths are used to construct these doses: 300 mg is achieved with two 150 mg capsules twice daily, and 400 mg is achieved with two 200 mg capsules twice daily. Capsules must be swallowed whole with water and taken on an empty stomach; food significantly increases the absorption of nilotinib and may increase the risk of side effects. Patients should not eat for at least 2 hours before and at least 1 hour after taking a dose. If a dose is missed, the patient should take the next dose at the usual time; two doses must not be taken at the same time. Dose adjustments may be required for QT prolongation, myelosuppression, or hepatic impairment. The tablets/capsules should not be opened or crushed.
Dosage form: Hard gelatin capsules: 150 mg (red/white, size 1) and 200 mg (light blue/white, size 0). Available in blister packs of 28 or 30 capsules.
Onset of action: Peak plasma concentrations are reached approximately 3 hours after oral administration. Steady‑state plasma levels are achieved by day 8 of twice‑daily dosing. Hematologic response in newly diagnosed CML is typically observed within the first 1 to 3 months, with major molecular response developing over 12 to 18 months of continuous therapy.
Duration of action: The elimination half‑life of nilotinib is approximately 17 hours, supporting a twice‑daily dosing schedule. Therapeutic effect is maintained with continuous daily treatment; discontinuation can lead to disease recurrence and is considered only in selected patients with deep and sustained molecular response under specialist supervision.
Alcohol recommendation: Alcohol should be avoided during treatment with Tasigna. Alcohol may increase the risk of hepatotoxicity and can exacerbate gastrointestinal side effects. Nilotinib can prolong the QT interval, and excessive alcohol consumption may further increase the risk of cardiac arrhythmias. Patients should be counselled to abstain from alcohol while on this medication.
Most common side effects: Rash, pruritus, headache, nausea, fatigue, myalgia, constipation, diarrhea, and peripheral edema. Myelosuppression, including thrombocytopenia, neutropenia, and anemia, is common and requires regular complete blood count monitoring, especially during the first few months of therapy. Nilotinib can cause prolongation of the QT interval; an electrocardiogram should be obtained at baseline and periodically thereafter, and the drug should be used with caution in patients with a history of QT prolongation or those taking other QT‑prolonging drugs. Metabolic abnormalities include hyperglycemia and hyperlipidemia; fasting glucose and lipid profiles should be monitored. Serious vascular events, including peripheral arterial occlusive disease, ischemic heart disease, and cerebrovascular events, have been reported with nilotinib; patients with cardiovascular risk factors require close monitoring. Hepatotoxicity, pancreatitis, and fluid retention have also been observed. Tumour lysis syndrome may occur in patients with high tumour burden; adequate hydration and uric acid control are important. Women of childbearing potential must use effective contraception during treatment and for at least 14 days after the last dose, as nilotinib may cause fetal harm. Tasigna is available only by prescription and must be prescribed and supervised by a healthcare professional experienced in oncology or hematology.
Would you like to try Tasigna (Nilotinib) without a prescription?
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
+ Package delivery insurance
+ Next orders 10% discount
